Illumina Q4 Earnings & Revenues Top Estimates, Stock Dips

Core Insights - Illumina Inc. reported fourth-quarter 2025 adjusted EPS of $1.35, exceeding the Zacks Consensus Estimate by 7.4% and reflecting a year-over-year increase of 42.1% [1] - The company's GAAP EPS was $2.16, significantly higher than 73 cents a year ago [1] - Full-year adjusted EPS reached $4.84, marking a 16.3% increase year over year [1] Revenue Performance - Fourth-quarter revenues were $1.16 billion, up 5.4% year over year and slightly above the Zacks Consensus Estimate by 0.3% [2] - Full-year revenues totaled $4.34 billion, a modest increase of 0.2% year over year, remaining flat on a constant-currency basis [2] - Following the earnings announcement, Illumina's shares fell by 10.4%, attributed to concerns over gross margin contraction [2] Segment Analysis - Revenues from the Product segment amounted to $990 million, reflecting a 5.4% year-over-year increase [3] - Services and other revenues were $169 million, up 2.4% year over year [3] Margin Analysis - The adjusted gross margin was 65.5%, down 45 basis points year over year due to a 6.4% increase in the cost of revenues [4] - Research and development expenses decreased by 6.6% year over year to $239 million, while SG&A expenses totaled $310 million, down 11.1% from the previous year [4] - Adjusted operating margin expanded by 64 basis points to 63.7% [4] Financial Position - At the end of the fourth quarter of 2025, Illumina had cash and cash equivalents of $1.42 billion, up from $1.13 billion at the end of the fourth quarter of 2024 [5] - Cumulative net cash provided by operating activities was $1.08 billion, compared to $837 million a year ago [5] Future Guidance - For 2026, Illumina expects total revenues to be in the range of $4.50 billion to $4.60 billion, indicating growth of 4-6% on a reported basis [6] - The Zacks Consensus Estimate for 2026 revenues is currently at $4.54 billion [6] - Non-GAAP diluted EPS is projected to be between $5.05 and $5.20 in 2026, with the Zacks Consensus Estimate for full-year EPS at $5.14 [9] Strategic Developments - Notable developments in the quarter included the acquisition of SomaLogic and the launch of the Billion Cell Atlas, aimed at supporting AI-enabled drug discovery [10]